Premenstrual Dysphoric Disorder (PMDD)

Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder in which significant depression, irritability, anxiety or mood swings appear in the week or so before menstruation and improve within a few days of its onset, following a pattern that repeats most cycles. It is far more disabling than ordinary premenstrual syndrome (PMS): where PMS involves mild physical and emotional discomfort that most women manage without difficulty, PMDD causes symptoms severe enough to significantly disrupt work, relationships and daily functioning, and is associated with a meaningfully elevated risk of suicidal thinking during the symptomatic window. PMDD is frequently under-recognised, in Nepal and elsewhere, because symptoms are dismissed as 'just PMS' or attributed to a difficult personality, when in fact it is a diagnosable psychiatric condition with a specific, evidence-based treatment approach, and confirming the cyclical pattern through symptom tracking is central to getting an accurate diagnosis.

PMDD is diagnosed when at least five of eleven specified symptoms — including marked affective lability, irritability, depressed mood, anxiety, and physical symptoms such as breast tenderness or bloating — are present in the final week before menses in most menstrual cycles over the preceding year, begin to improve within a few days after menses starts, and are minimal or absent in the week after menses, with at least one core mood symptom (marked lability, irritability, depressed mood, or anxiety) required, and the symptoms causing clinically significant distress or functional impairment.

PMDD is understood as an abnormal sensitivity of the brain to normal cyclical hormonal fluctuations — particularly the fall in oestrogen and progesterone in the luteal phase — rather than an abnormality of hormone levels themselves, which are typically normal on testing. This heightened sensitivity affects neurotransmitter systems, particularly serotonin, which explains both the mood symptoms and the effectiveness of serotonergic medication. Genetic vulnerability, a personal history of depression or anxiety, and high stress can all increase the likelihood or severity of PMDD.

• Personal history of depression, anxiety, or postpartum depression
• Family history of PMDD or mood disorders
• History of trauma or high chronic stress
• Sensitivity to hormonal changes at other times, such as during pregnancy or perimenopause
• Smoking
• Underlying, less severe premenstrual syndrome that intensifies over time

In women with PMDD, the normal luteal-phase decline in oestrogen and progesterone — and specifically the neurosteroid allopregnanolone, a progesterone metabolite that acts on GABA receptors — appears to trigger an abnormal response in mood-regulating brain circuits, rather than reflecting any abnormal hormone level itself. Serotonergic pathways are strongly implicated, since serotonergic antidepressants are effective even when dosed only during the luteal phase, faster-acting than their typical onset in standard depression treatment — a distinctive pharmacological feature that supports the theory of an acute neurosteroid-triggered mechanism rather than a slower monoamine-depletion process.

• Marked mood swings (suddenly feeling sad, tearful, or sensitive to rejection)
• Marked irritability, anger, or increased conflict with others
• Depressed mood, hopelessness, or self-critical thoughts
• Marked anxiety, tension, or feeling on edge
• Decreased interest in usual activities
• Difficulty concentrating
• Fatigue or low energy
• Change in appetite, food cravings, or overeating
• Sleep disturbance — sleeping too much or too little
• A sense of being overwhelmed or out of control
• Physical symptoms: breast tenderness, bloating, joint or muscle pain, weight gain sensation

• At least 5 of 11 specified symptoms present in the final week before menses, with at least one being marked affective lability, irritability, depressed mood, or anxiety
• Symptoms begin to improve within a few days after the onset of menses and become minimal or absent in the week post-menses
• The pattern is confirmed by prospective daily symptom ratings over at least two menstrual cycles, not by retrospective recall alone
• Symptoms are associated with clinically significant distress or interference with work, school, social activities or relationships
• The disturbance is not merely an exacerbation of another disorder, such as major depressive disorder, though PMDD can co-occur with other conditions

Conditions a psychiatrist will consider and rule out before confirming this diagnosis:

Premenstrual syndrome (PMS)

PMS involves milder physical and emotional symptoms that do not cause the marked functional impairment or the required core mood symptoms seen in PMDD.

Major depressive disorder or an anxiety disorder

These involve persistent symptoms not tied to a specific cyclical pattern; a mood disorder that is present throughout the cycle, not just the luteal phase, points away from PMDD, though the two can coexist and PMDD can premenstrually worsen an underlying condition.

Perimenopause

Perimenopausal mood symptoms can also fluctuate but are tied to the broader hormonal transition of perimenopause rather than a consistent monthly premenstrual pattern.

Thyroid dysfunction

Can cause mood and energy symptoms that may be mistaken for a cyclical pattern; thyroid function should be checked if symptoms don't clearly follow the classic premenstrual timing.

• Prospective daily symptom tracking across at least two menstrual cycles using a structured symptom diary — the central diagnostic tool
• Clinical interview covering psychiatric history, current mood symptoms across the whole cycle, and functional impact
• Screening for comorbid depression, anxiety and trauma history
• Basic evaluation to exclude thyroid or other medical contributors when the pattern is unclear

First-line treatment for PMDD is an SSRI antidepressant, which can be taken either continuously or, distinctively, only during the luteal phase (the two weeks before menses), often working faster than in standard depression treatment. Hormonal approaches, including certain combined oral contraceptives, are an alternative or additional option for some women. Lifestyle measures, structured symptom tracking to anticipate and plan around difficult days, and psychological support for the relationship and functional strain PMDD can cause are useful complements to medical treatment. Because symptoms are cyclical, treatment plans are often adjusted around the individual's own confirmed pattern rather than following a fixed daily regimen used for other depressive disorders.

SSRIs (e.g. sertraline, fluoxetine, escitalopram)

First-line treatment, effective when taken either continuously or only during the luteal phase for many women — a dosing flexibility distinctive to PMDD compared with standard depression treatment.

Combined hormonal contraceptives

Certain formulations, particularly continuous or extended-cycle regimens, can reduce PMDD symptoms for some women by minimising hormonal fluctuation, though response varies and some women feel worse on hormonal contraception.

GnRH agonists (specialist use)

Reserved for severe, treatment-resistant cases under specialist supervision, given their significant side-effect profile and typical use as an add-back regimen.

Cognitive behavioural therapy (CBT)

Helps build coping strategies for the luteal-phase symptomatic window and address the impact on relationships, work and self-esteem, with evidence for meaningful symptom reduction.

Psychoeducation and cycle-based planning

Using confirmed symptom-tracking data to anticipate difficult days and plan workload, communication and self-care accordingly reduces both symptom impact and the sense of unpredictability many women describe.

• Keep a consistent daily symptom diary across cycles — this is both diagnostic and useful for anticipating difficult days
• Prioritise regular sleep, moderate exercise and consistent meals, particularly in the luteal phase
• Reduce caffeine, alcohol and added salt in the days before menses, which some women find eases physical symptoms
• Plan lower-demand scheduling where possible around known symptomatic days
• Build a support plan with close family or a partner, since many women describe real relationship strain during symptomatic days
• Practice stress-reduction techniques such as regular exercise, mindfulness or breathing exercises

PMDD responds well to treatment for most women, whether through SSRIs, hormonal approaches, or a combination with psychological support, with many experiencing substantial symptom relief. Because the underlying cyclical trigger persists until menopause, PMDD tends to be a long-term, cycle-linked condition requiring an ongoing management plan rather than a one-time treatment, though symptoms typically resolve after menopause. Untreated PMDD is associated with a meaningfully elevated risk of suicidal thinking during symptomatic days, which makes accurate diagnosis and treatment particularly important, not merely a quality-of-life issue.

• Track symptoms early if a cyclical pattern is suspected, rather than waiting years for a diagnosis
• Maintain consistent sleep, exercise and stress-management habits, which reduce symptom severity for many women
• Seek treatment for underlying depression or anxiety, which can amplify premenstrual symptoms
• Build a proactive plan for luteal-phase workload and self-care once the pattern is confirmed

PMDD is a real, biologically driven psychiatric condition, not a matter of a woman being 'too sensitive' or intentionally difficult, and it is important that partners and family understand this rather than adding blame or dismissal to an already distressing cyclical pattern. Support can include understanding the symptom-tracking process, being flexible around confirmed difficult days, and encouraging treatment rather than expecting the person to simply manage it alone each month. Because PMDD carries a real elevated risk of suicidal thinking during symptomatic days, family awareness of warning signs and encouragement to seek psychiatric care is genuinely protective, not an overreaction.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR).
2. American College of Obstetricians and Gynecologists (ACOG). Premenstrual syndrome and premenstrual dysphoric disorder clinical guidance.
3. International Association for Premenstrual Disorders (IAPMD) clinical resources.